In what clinical scenarios do you utilize venetoclax-based therapy in relapsed/refractory multiple myeloma?

I would caution that there is no strong data that the combination of Venetoclax with a proteasome inhibitor or a CD38 antibody makes sense; in fact, the addition is more likely than not to cause harm.

Adding on to Venetoclax in patients that are naive to proteasome inhibitor or CD38 Ab naive is jus...

Disclaimer, before I comment, is that venetoclax is not FDA approved for myeloma and any use is off-label. The results for those with t(11;14) or high BCL2 expression are promising, but the phase 3 BELLINI study of Ven-Vd vs Vd showed inferior OS for Ven-Vd. This was mostly due to infection risk. So...

Excellent question. Others (@Dr. First Last and @Dr. First Last) had answered several of these subquestions in a prior thread here:

https://www.themednet.org/question/10770.

But we didn't fully address the ideal combo regimen to use in the appropriate setting - e.g., t(11;14) still present by FISH [BC...